CervoMed (CRVO) said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.
Shares slumped 77% as intraday trading volume soared to over 6.44 million from a daily average of about 122,000.
MEDIROM Healthcare Technologies (MRM) shares tumbled 45% amid heavy trading after the company unveiled late Monday an offering of 2.86 million American Depositary Shares at $1.75 each, targeting gross proceeds of about $5 million.
More than 1.51 million shares traded intraday compared with a daily average of about 117,000.
Biora Therapeutics (BIOR) said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement.
Shares sank 60%, with intraday trading volume at over 1.39 million versus a daily average of about 88,000.
Price: 2.36, Change: -7.89, Percent Change: -76.98
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。